UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042852
Receipt number R000048915
Scientific Title Assessment of beneficial effects on sympathetic nerve activity by pemafibrate in hypertriglyceridemic patients with obesity and hypertension
Date of disclosure of the study information 2021/01/05
Last modified on 2020/12/25 15:25:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of PEmafibRate on Sympathetic nErve fUnction in hypertriglyceridemia patients with obeSity and hypertension

Acronym

Perseus study

Scientific Title

Assessment of beneficial effects on sympathetic nerve activity by pemafibrate in hypertriglyceridemic patients with obesity and hypertension

Scientific Title:Acronym

Perseus study

Region

Japan


Condition

Condition

Obesity, Hypertension, Dyslipidemia

Classification by specialty

Medicine in general Cardiology Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study is to observe the effect of pemafibrate on sympathetic nervous activity in patients with hypertriglyceridemia associated with obesity and hypertension.

Basic objectives2

Others

Basic objectives -Others

To observe the effect of pemafibrate on sympathetic nervous activity

Trial characteristics_1

Others

Trial characteristics_2


Developmental phase

Phase IV


Assessment

Primary outcomes

Change in LF/HF from baseline at 24 weeks post-treatment

Key secondary outcomes

1. Change in HF and LF from baseline at 24 weeks after initiation of treatment
2. Change from baseline at 24 weeks after the start of study treatment for the following
1) Change in heart rate variability index
2) Frequency of extrasystoles and arrhythmias
3) Body measurements: weight, BMI
4) Carotid artery IMT
5) Abdominal circumference, Catecholamine, General blood collection results


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

1.Patients diagnosed with dyslipidemia (TG >150 mg/dL at any time) and scheduled to receive pemafibrate.
2. obese patients
3. Patients with hypertension
4. Patients who have given written consent to participate in the clinical study

Key exclusion criteria

1. Patients with contraindications to the target drug.
2. Patients with chronic atrial fibrillation or pacemaker implantation
Patients with severe impairment of cardiovascular or pulmonary function such as shock, heart failure, myocardial infarction, pulmonary embolism, and other patients prone to hypoxemia.
4. Patients with excessive alcohol intake
5. Patients with severe infections, before and after surgery, or with severe trauma
Patients with malnutrition, starvation, weakness, pituitary insufficiency, or adrenal insufficiency.
7. Other patients who are deemed inappropriate by the attending physician.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Koh
Middle name
Last name Ono

Organization

Kyoto University Graduate School of Medicine

Division name

Department of Cardiovascular Medicine

Zip code

6068507

Address

54 Shogoinkawahara-cho, Sakyo-ku, Kyoto

TEL

0757513190

Email

kohono@kuhp.kyoto-u.ac.jp


Public contact

Name of contact person

1st name Koh
Middle name Ono
Last name Ono

Organization

Kyoto University Graduate School of Medicine

Division name

Department of Cardiovascular Medicine

Zip code

6068507

Address

54 Kawahara-cho Shogoin, Sakyo-ku

TEL

0757513190

Homepage URL


Email

kohono@kuhp.kyoto-u.ac.jp


Sponsor or person

Institute

Department of Cardiovascular Medicine, Kyoto University Hospital

Institute

Department

Personal name



Funding Source

Organization

Self-adjustment

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Kyoto


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kyoto University Graduate School and Faculty of Medicine, Ethics Committee

Address

Yoshidakonoe-cho, Sakyo-ku, Kyoto

Tel

0757534680

Email

ethcom@kuhp.kyoto-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

京都大学医学部付属病院(京都府)


Other administrative information

Date of disclosure of the study information

2021 Year 01 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2020 Year 10 Month 20 Day

Date of IRB

2020 Year 10 Month 20 Day

Anticipated trial start date

2021 Year 01 Month 06 Day

Last follow-up date

2022 Year 10 Month 20 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Registration period for research subjects
One year from the date of ethical review approval.
However, the registration period will be shortened if the expected number of cases is reached early.


Management information

Registered date

2020 Year 12 Month 25 Day

Last modified on

2020 Year 12 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048915


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name